With 0.72 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.53 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.705 whereas the lowest price it dropped to was $2.475. The 52-week range on PRQR shows that it touched its highest point at $4.62 and its lowest point at $1.61 during that stretch. It currently has a 1-year price target of $8.28. Beta for the stock currently stands at 0.31.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PRQR was down-trending over the past week, with a drop of -7.07%, but this was down by -28.34% over a month. Three-month performance surged to 56.55% while six-month performance rose 59.39%. The stock gained 34.18% in the past year, while it has gained 32.83% so far this year. A look at the trailing 12-month EPS for PRQR yields -0.32 with Next year EPS estimates of -0.43. For the next quarter, that number is -0.10. This implies an EPS growth rate of 3.42% for this year and -19.92% for next year.
Float and Shares Shorts:
At present, 81.68 million PRQR shares are outstanding with a float of 74.28 million shares on hand for trading. On 2024-11-29, short shares totaled 0.19 million, which was 18.000000999999997 higher than short shares on 1730332800. In addition to Mr. Daniel Anton de Boer as the firm’s Founder, CEO & Member of Management Board, Dr. Domenico Valerio Ph.D. serves as its Founder & Independent Member of Supervisory Board.
Institutional Ownership:
Through their ownership of 0.24958 of PRQR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, PRQR reported revenue of $3843000.0 and operating income of -$8854000.0. The EBITDA in the recently reported quarter was -$8166000.0 and diluted EPS was -$0.1.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PRQR since 5 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PRQR analysts setting a high price target of 14.0 and a low target of 4.0, the average target price over the next 12 months is 8.0. Based on these targets, PRQR could surge 432.32% to reach the target high and rise by 52.09% to reach the target low. Reaching the average price target will result in a growth of 204.18% from current levels.
Analysts have provided yearly estimates in a range of -$0.22884 being high and -$0.41608 being low. For PRQR, this leads to a yearly average estimate of -$0.32246.
